Xilio Therapeutics, Inc. (XLO) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
828 Winter Street
Waltham, MA 02451
United States of America (the)
Phone
617 430 4680
Website
Sector
Healthcare
Industry
Biotechnology
Employees
64
First IPO Date
October 22, 2021
| Name | Title | Pay | Year Born |
| Rene Russo BCPS | President, Chief Executive Officer & Director | 1.16M | 1975 |
| Katarina Luptakova | Chief Medical Officer | 691,670 | 1976 |
| Christopher Frankenfield | Chief Financial Officer & Chief Operating Officer | 941,594 | 1982 |
| Uli Bialucha | Chief Scientific Officer | 0 | N/A |
| Ruth du Moulin | Senior Vice President of Medical Affairs | 0 | N/A |
| Scott Coleman | Chief Development Officer | 0 | N/A |
| Kevin Brennan | Senior Vice President of Finance & Accounting | 0 | 1970 |
| Nathan McBride | Chief Information Officer | 0 | N/A |
| Caroline Hensley | Chief Legal Officer | 0 | N/A |
Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for various solid tumors. The company also develops a range of cytokine programs, including XTX202 (a modified IL-2), XTX301 (an IL-12 product candidate), and XTX401 (an IL-15 product candidate). These cytokine therapies are ingeniously engineered with a protein domain that keeps them inactive until proteases specific to the tumor microenvironment (TME) cleave this mask, thereby initiating their therapeutic activity. Xilio Therapeutics, Inc. was founded in 2016 and is based in Waltham, Massachusetts.